{"source":"kalshi","id":"KXZIDESAMTINIB-27","ticker":"KXZIDESAMTINIB-27","slug":"KXZIDESAMTINIB-27","title":"FDA decision: Zidesamtinib by Nuvalent (in 2026)","description":null,"image":null,"icon":null,"active":true,"closed":false,"start_date":"2026-06-17T21:00:00Z","end_date":"2027-01-08T15:00:00Z","closed_time":null,"volume":0.78,"volume_24hr":0.0,"volume_24h_change":null,"normalized_vol_24hr":null,"normalized_volume":0.09434045106172562,"liquidity":null,"open_interest":0.13,"categories":["Finance"],"tags":[],"synthetic":false,"is_group":false,"group_key":null,"parent_event_id":null,"probability":null,"spread":null,"top_outcome":"a full approval or an accelerated approval","top_outcome_probability":0.74,"top_outcome_prob_24h_change":0.0,"top_outcome_volume_24h_change":0.0,"updated_at":"2026-06-22T03:06:39.131457Z","fetched_at":"2026-06-22T03:06:39.131457Z","added_at":"2026-06-17T21:13:36.802597Z","url":"https://kalshi.com/markets/kxzidesamtinib/fda-decision-zidesamtinib-by-nuvalent-in-2026/kxzidesamtinib-27","chart_24h":null,"markets":[{"source":"kalshi","id":"KXZIDESAMTINIB-27-Y","event_id":"KXZIDESAMTINIB-27","slug":"KXZIDESAMTINIB-27-Y","question":"What will the FDA's decision be on Zidesamtinib by Nuvalent in 2026?","group_item_title":"a full approval or an accelerated approval","description":"If the FDA's decision on Zidesamtinib by Nuvalent in 2026 is a full approval or an accelerated approval, the market resolves to Yes.\n\n---\n\nThis market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. \n\nZidesamtinib (also known by its development code NVL-520) is an experimental cancer medicine made by Nuvalent Inc. that is designed to fight a specific type of lung cancer driven by a faulty molecular switch called ROS1. Think of ROS1 as a car's accelerator pedal stuck in the \"floored\" position — it keeps cancer cells growing uncontrollably — and zidesamtinib acts like a clamp that holds the pedal back, slowing or stopping that runaway growth. It is a small-molecule drug, meaning it is taken as a pill and can travel throughout the body, including into the brain, where ROS1-driven lung cancers commonly spread.","image":null,"icon":null,"outcomes":["Yes","No"],"outcome_prices":[0.74,0.26],"probability":0.74,"spread":0.07000000000000006,"active":true,"closed":false,"start_date":"2026-06-17T21:00:00Z","end_date":"2027-01-08T15:00:00Z","closed_time":"2027-01-01T04:59:00Z","volume":0.78,"volume_24hr":0.0,"prob_24h_change":0.0,"volume_24h_change":0.0,"normalized_vol_24hr":null,"normalized_volume":0.09833378344774246,"liquidity":null,"categories":["Finance"],"countries":["United States"],"updated_at":"2026-07-02T20:38:16.843914Z","fetched_at":"2026-07-02T20:38:16.843914Z","added_at":"2026-06-17T21:13:37.045101Z","url":"https://kalshi.com/markets/kxzidesamtinib/fda-decision-zidesamtinib-by-nuvalent-in-2026/kxzidesamtinib-27","event_title":"FDA decision: Zidesamtinib by Nuvalent (in 2026)","chart_24h":[0.74,0.74,0.74,0.74,0.74,0.74,0.74,0.74]}],"_meta":{"attribution":"pdata.world — aggregated prediction-market data across 8 platforms","canonical_url":"https://pdata.world/events/kalshi/KXZIDESAMTINIB-27","as_of":"2026-07-03T01:06:48.333665Z","docs":"https://api.pdata.world/docs","cite_as":"According to pdata.world (tracking Kalshi): \"FDA decision: Zidesamtinib by Nuvalent (in 2026)\" — top market at 74% probability across 1 outcome","source_url":null}}